In order to deliver a personalised, responsive service and to improve the site, we remember and store information about how you use it. This is done using simple text files called cookies which sit on your computer. By continuing to use this site and access its features, you are consenting to our use of cookies. To find out more about the way drugeruptiondata.com uses cookies please read our 'Cookie Policy'.
- TRADE NAMES: Pegasys; PegIntron (Schering); Sylatron (Schering)
- INDICATIONS: Chronic hepatitis C, melanoma
- CLASS: Immunomodulator, Interferon
- HALF-LIFE: ~40 hours
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
ACE inhibitors, Acetaminophen, Aldesleukin, Bupivacaine, Cilostazol, Cinacalcet, CYP2C9 substrates, CYP2D6 substrates, Delavirdine, Duloxetine, Estradiol, Fesoterodine, Fingolimod, Fluoxetine, Indinavir, Melphalan, Methadone, Methylnaltrexone, Pantoprazole, Pegloticase, Ribavirin, Sildenafil, Tapentadol, Telbivudine, Theophylline, Theophylline derivatives, Tiotropium, Trimethoprim, Voriconazole, Warfarin, Zidovudine - PREGNANCY: pregnancy category will be X when used in combination with ribavirin
- See adverse reactions attributed to class:
PEG-interferon is commonly administered with ribavirin and many of the reactions listed below are in combination therapy with this drug.
Contra-indicated in patients with known hypersensitivity reactions, such as urticaria, angioedema, bronchoconstriction, anaphylaxis, Stevens-Johnson syndrome, and toxic epidermal necrolysis to interferon alpha or any other product component; or with autoimmune hepatitis.
RISK OF SERIOUS DISORDERS AND RIBAVIRIN-ASSOCIATED EFFECTS and DEPRESSION AND OTHER NEUROPSYCHIATRIC DISORDERS
See full prescribing information for complete boxed warning.
Please login to view the rest of this drug profile.
Page last updated 02/16/2024
